ConductScience.org, home
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
API referenceFor AI assistants

Trial · NCT03214952

Results by group36

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 36

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants With Gastric Ulcer Who Had One or More Adverse Drug ReactionsVonoprazan 20 mg1.00Percentage of Participants
Percentage of Participants With Duodenal Ulcer Who Had One or More Adverse Drug ReactionsVonoprazan 20 mg1.21Percentage of Participants
Percentage of Participants With Reflux Esophagitis Who Had One or More Adverse Drug ReactionsVonoprazan 20 mg0.78Percentage of Participants
Endoscopic Cure Rate in Participants With Gastric UlcerVonoprazan 20 mg78.7295% Confidence Interval 74.80 to 82.28Percentage of Participants
Endoscopic Cure Rate in Participants With Duodenal UlcerVonoprazan 20 mg88.4695% Confidence Interval 83.66 to 92.26Percentage of Participants
Endoscopic Cure Rate in Participants With Reflux EsophagitisVonoprazan 20 mg65.0495% Confidence Interval 58.44 to 71.25Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgHeartburn96.6895% Confidence Interval 93.28 to 98.66Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgAcid Reflux96.8695% Confidence Interval 92.81 to 98.97Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgPostprandial Fullness96.0995% Confidence Interval 93.27 to 97.96Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgEarly Satiation97.0895% Confidence Interval 93.31 to 99.04Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgEpigastric Pain98.7895% Confidence Interval 97.60 to 99.47Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgEpigastric Burning97.6295% Confidence Interval 94.02 to 99.35Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgAbdominal Bloating95.6595% Confidence Interval 91.91 to 97.99Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgNausea/Vomiting97.5295% Confidence Interval 94.68 to 99.08Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgBelching91.6795% Confidence Interval 85.21 to 95.93Percentage of Participants
Percentage of Participants With Gastric Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgAnorexia98.2295% Confidence Interval 96.17 to 99.34Percentage of Participants
Percentage of Participants With Duodenal Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgHeartburn96.9495% Confidence Interval 91.31 to 99.36Percentage of Participants
Percentage of Participants With Duodenal Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgAcid Reflux97.2295% Confidence Interval 90.32 to 99.66Percentage of Participants
Percentage of Participants With Duodenal Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgPostprandial Fullness95.6595% Confidence Interval 90.78 to 98.39Percentage of Participants
Percentage of Participants With Duodenal Ulcer Whose Subjective Symptoms ImprovedVonoprazan 20 mgEarly Satiation98.7895% Confidence Interval 93.39 to 99.97Percentage of Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03214952/results

API referenceFor AI assistants